India, Nov. 4 -- Glenmark Pharmaceuticals Inc., USA has announced the upcoming launch of its 8.4% Sodium Bicarbonate Injection USP (50 mEq/50 mL, 1 mEq/mL) in a single-dose vial. The product is bioequivalent and therapeutically equivalent to Abbott Laboratories' reference drug approved under NDA 019443. Distribution is expected to begin in November 2025.
According to IQVIA data for the 12 months ending August 2025, the market for this product category recorded sales of around $63.8 million.
Marc Kikuchi, President & Business Head – North America, said the launch strengthens Glenmark's injectable portfolio and reflects its commitment to providing accessible and affordable treatment alternatives.
Note: The product is approved only fo...